INTRODUCTION
• Hyperhidrosis affects an estimated 4.8% of the US population 1 ; approximately three-quarters of patients experience negative psychological effects, with anxiety and depression occurring over 3.5-times more frequently in people with hyperhidrosis than in people without it 1, 2 • Despite high prevalence and burden of disease, few disease-specific outcome measures are available -The Hyperhidrosis Disease Severity Scale (HDSS) is widely used in clinical studies and well understood in clinical practice; however, it does not conform to current regulatory standards for patient-reported outcome (PRO) measures used to support product approvals and labeling
• The 4-item Axillary Sweating Daily Diary (ASDD; Table 1 ) and a child-specific 2-item version (ASDD-C for use in patients ≥9 to <16 years of age; Table 1) were developed according to current regulatory standards 3
-The ASDD/ASDD-C axillary sweating severity item (Item 2) was specifically developed for use as an endpoint in clinical trials in support of approval and labeling (and also as a useful clinical parameter)
• In addition to the ASDD, patients ≥16 years of age were asked to complete 6 Weekly Impact Items designed to assess the impact and bother of hyperhidrosis on daily activities and a single-item Patient Global Impression of Change (PGIC) to assess overall change in sweating severity ( Table 1) • Initial psychometric evaluation of the ASDD was conducted using data from a phase 2 study of topical glycopyrronium tosylate (GT; formerly DRM04), an investigational treatment for primary axillary hyperhidrosis in patients ≥9 years of age; results have been previously reported and provide preliminary support for the use of this measure to evaluate the efficacy of axillary hyperhidrosis treatment in clinical trials 4
OBJECTIVE
• To confirm and extend the psychometric evidence supporting ASDD/ASDD-C axillary sweating severity item (Item 2) based on pooled data from two phase 3 clinical trials of GT: ATMOS-1 (DRM04-HH04; NCT02530281) and ATMOS-2 (DRM04-HH05; NCT02530294)
METHODS

Study Design
• ATMOS-1 and ATMOS-2 were phase 3, multicenter (ATMOS-1: sites in US and Germany; ATMOS-2: sites in US), parallel-group, 4-week, double-blind clinical trials in which patients with primary axillary hyperhidrosis were randomized (2:1)
to GT or vehicle
• Eligible patients were ≥9 years of age (patients <16 years were only recruited at US sites) and had primary axillary hyperhidrosis for ≥6 months, with gravimetrically-measured sweat production of ≥50 mg/5 min in each axilla, ASDD/ASDD-C axillary sweating severity item (Item 2) score ≥4, and
Hyperhidrosis Disease Severity Scale (HDSS) grade 3 or 4
Assessments
• Axillary Hyperhidrosis Patient Measures (AHPM)
-ASDD/ASDD-C Item 2 responses and sweat production were assessed in two age groups (≥9 years and ≥16 years)
-ASDD/ASDD-C items were scored as a weekly average of daily responses; at least 4 days of daily data were required for analysis -Weekly Impact Items and PGIC were included to evaluate construct validity
Psychometric Evaluation
• Potential floor and ceiling effects and nonresponse bias were evaluated based on both summary statistics and graphical techniques
• Test-retest reliability was evaluated through the computation of intraclass correlation coefficients (ICCs) between Week 3 and Week 4; a value ≥0.70 was considered acceptable
• Construct validity was evaluated at Week 4 based on correlations between ASDD/ASDD-C Item 2 and ASDD items related to the impact and bother of sweating (Items 3 and 4, respectively), HDSS, sweat production, and other PRO measures as available
• All statistical tests were two-tailed using a type I error rate of 1% (alpha=0.01) 
Item 4
During the past 24 hours, how bothered were you by your underarm sweating?
(not at all bothered), 1 (a little bothered), 2 (moderately bothered), 3 (very bothered), 4 (extremely bothered)
Axillary Sweating Daily Diary-Children (ASDD-C) c
Instructions: These questions measure how bad your underarm sweating was last night and today. Please think only about your underarm sweating when answering these questions. Please complete these questions each night before you go to sleep.
Item 1 [Gatekeeper]
Thinking about last night and today, did you have any underarm sweating? Yes/No When Item 1 is answered "no," Item 2 is skipped and scored as zero 
Yes/ No
f. During the past 7 days, did your underarm sweating ever keep you from doing an activity you wanted or needed to do?
Patient Global Impression of Change (PGIC) Item b
Overall, how would you rate your underarm sweating now as compared to before starting the study treatment?
(much better), 2 (moderately better), 3 (a little better), 4 (no difference), 5 (a little worse), 6 (moderately worse), 7 (much worse)
aASDD/ASDD-C Item 2 is a validated PRO measure bFor use in patients ≥16 years of age cFor use in patients ≥9 to < 16 years of age
RESULTS
• The pooled phase 3 study population (N=697) included 665 patients who were ≥16 years of age and 32 patients who were ≥9 to <16 years of age ( Table 2) • The response distribution for the ASDD/ASDD-C axillary sweating severity item (Item 2) demonstrated no floor or ceiling effect, and no nonresponse bias (Table 3) • Construct validity was supported by strong correlations between ASDD Item 2 and the ASDD items addressing the impact and bother of axillary sweating (Items 3 and 4, respectively) ( Table 3) • Test-retest reliability was supported by ICCs of 0.93 for both age subgroups (Table 3) , which is well above the 0.70 criterion, and within the confidence interval of the phase 2 estimate of 0.91 (95% CI: 0.87, 0.94) 4
• The ASDD/ASDD-C Item 2 responsiveness, or ability to detect change in sweating severity, was demonstrated by large effect sizes and correlations that were within the expected range for the change in ASDD/ASDD-C Item 2 and the change in the gravimetric measures of sweat production ( Table 3) 
CONCLUSIONS
• The current study confirms and extends the psychometric evidence supporting the ASDD/ASDD-C as a new PRO measure developed according to current regulatory standards
